ArmaGen reports 52-week Phase II data for MPS I candidate

ArmaGen Inc. (Calabasas, Calif.) reported data from stage 2 of the Phase II portion of a Phase I/II trial in patients ages two and older with severe mucopolysaccharidosis I (MPS I, Hurler syndrome) showing that

Read the full 358 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE